{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T05:11:45Z","timestamp":1697605905349},"reference-count":49,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2007,6,12]],"date-time":"2007-06-12T00:00:00Z","timestamp":1181606400000},"content-version":"vor","delay-in-days":2353,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Congestive Heart Failure"],"published-print":{"date-parts":[[2001,1]]},"abstract":"<jats:p> <jats:italic>Atrial fibrillation is a common arrhythmia in patients with heart failure. The presence of atrial fibrillation deteriorates cardiac function and increases the risk of thromboembolic events. The management of patients with atrial fibrillation in association with heart failure should consist of ventricular rate control, prevention of thromboembolic events, and conversion to normal sinus rhythm. Traditionally, digoxin has been widely used in patients with heart failure and atrial fibrillation; however, it does very little to restore sinus rhythm and requires the addition of another rate\u2010limiting agent to control ventricular rate. The likelihood of successful cardioversion is dependent on the duration of heart failure and the degree of neurohormonal activation. The initiation of antiarrhythmic drug therapy in patients with heart failure should be guided by safety issues as well as consideration of potential benefits vs. risks associated with therapy. Amioarone has been evaluated in numerous clinical trials and appears to be safe and effective when used in low dosage. Treatment with dofetilide is another option. Comparative studies with oral dofetilide vs. amiodarone are needed to evaluate their efficacy in restoration and maintenance of sinus rhythm in patients with heart failure. Such trials will clearly define the role of dofetilide in the treatment of atrial fibrillation. Routine prophylactic use of antiarrhythmic drug therapy for chronic atrial fibrillation in the setting of heart failure is not recommended due to a low efficacy rate and high proarrhythmic risk. Anticoagulation with warfarin and rate control remain the standard therapy.<\/jats:italic> <\/jats:p>","DOI":"10.1111\/j.1527-5299.2001.990864.x","type":"journal-article","created":{"date-parts":[[2007,6,12]],"date-time":"2007-06-12T11:13:47Z","timestamp":1181646827000},"page":"22-29","source":"Crossref","is-referenced-by-count":3,"title":["Atrial Fibrillation in Patients with Heart Failure: Pharmacologic Options"],"prefix":"10.1111","volume":"7","author":[{"given":"Mazen S.","family":"Matalka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prakash C.","family":"Deedwania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,6,12]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510350050036"},{"key":"e_1_2_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)00713-4"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1995.00430050045005"},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)80348-9"},{"key":"e_1_2_4_6_2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/oxfordjournals.eurheartj.a062312","article-title":"Chronic atrial fibrillation: Epidemiologic features and 14 years follow\u2010up: A case control study","volume":"3","author":"Onundarson PT","year":"1987","journal-title":"Eur Heart J"},{"key":"e_1_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.84.1.40"},{"key":"e_1_2_4_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.77.4.309"},{"key":"e_1_2_4_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/18.suppl_C.45"},{"key":"e_1_2_4_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.93.6.1262"},{"key":"e_1_2_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00466-4"},{"key":"e_1_2_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(00)00908-5"},{"key":"e_1_2_4_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.82.4.1106"},{"key":"e_1_2_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(92)90003-6"},{"key":"e_1_2_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)02149-6"},{"key":"e_1_2_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1071-9164(05)80004-1"},{"key":"e_1_2_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(92)90705-4"},{"key":"e_1_2_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(90)90394-5"},{"key":"e_1_2_4_19_2","first-page":"1137","article-title":"Improvement in left ventricular systolic function after successful radiofrequency His bundle ablation for drug refractory, chronic atrial fibrillation and recurrent atrial flutter","volume":"72","author":"Heinz G","year":"1993","journal-title":"Am J Cardiol"},{"key":"e_1_2_4_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8159.1993.tb01714.x"},{"key":"e_1_2_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(94)90364-6"},{"key":"e_1_2_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(97)00254-4"},{"key":"e_1_2_4_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/23.10.882"},{"key":"e_1_2_4_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.82.1.60"},{"key":"e_1_2_4_25_2","doi-asserted-by":"crossref","unstructured":"RawlesJM.What is meant by a \u201ccontrolled\u201d ventricular rate?Br Heart J.1990;63:157\u2013161.","DOI":"10.1136\/hrt.63.3.157"},{"key":"e_1_2_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(89)90141-0"},{"key":"e_1_2_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)04440-2"},{"key":"e_1_2_4_28_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study (CIBIS) II: A randomised trial","volume":"353","author":"CIBIS II Investigators and Committees","year":"1999","journal-title":"Lancet"},{"key":"e_1_2_4_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199605233342101"},{"key":"e_1_2_4_30_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-9-199505010-00008"},{"key":"e_1_2_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(83)90002-9"},{"key":"e_1_2_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(83)90008-X"},{"key":"e_1_2_4_33_2","doi-asserted-by":"crossref","unstructured":"DeedwaniaPC SinghBN EllenbogenK et al.Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation. Observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF\u2010STAT).Circulation.1998;98:2574\u20132579.","DOI":"10.1161\/01.CIR.98.23.2574"},{"key":"e_1_2_4_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199712183372501"},{"key":"e_1_2_4_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1994.00420130036007"},{"key":"e_1_2_4_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)89116-3"},{"key":"e_1_2_4_37_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.114.5_Supplement.579S"},{"key":"e_1_2_4_38_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-106-4-503"},{"key":"e_1_2_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(91)90707-R"},{"key":"e_1_2_4_40_2","first-page":"1241","article-title":"Atrial fibrillation: Overview of therapeutic trials","volume":"14","author":"Sharif MN","year":"1998","journal-title":"Can J Cardiol"},{"key":"e_1_2_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(95)00595-1"},{"key":"e_1_2_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(00)00902-4"},{"key":"e_1_2_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)00710-9"},{"key":"e_1_2_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00395-0"},{"key":"e_1_2_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(96)00506-2"},{"key":"e_1_2_4_46_2","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.1999.2039"},{"key":"e_1_2_4_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(97)00157-5"},{"key":"e_1_2_4_48_2","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960200706"},{"key":"e_1_2_4_49_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199958060-00007"},{"key":"e_1_2_4_50_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909163411201"}],"container-title":["Congestive Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1527-5299.2001.990864.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1527-5299.2001.990864.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T09:40:59Z","timestamp":1697535659000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1527-5299.2001.990864.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,1]]}},"alternative-id":["10.1111\/j.1527-5299.2001.990864.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1527-5299.2001.990864.x","archive":["Portico"],"relation":{},"ISSN":["1527-5299","1751-7133"],"issn-type":[{"value":"1527-5299","type":"print"},{"value":"1751-7133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,1]]}}}